One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...
14don MSN
The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those results unsettled investors, setting off a three-week sello ...
Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales of its diabetes and obesity drugs Mounjaro and Zepbound. This is ...
Reports indicate he was actually taking Eli Lilly's (NYSE: LLY) weight-loss drug Mounjaro. Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon ...
This is an enormous opportunity, and Lilly's clinical pipeline looks well positioned. Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback